IP Library › Patent Application 17293358

Patent Application

App. No. 17/293,358

ANTIBACTERIAL COMPOUNDS

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 17/293,358

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. Furthermore, the subject compounds and compositions are useful for the treatment of bacterial infection, such as urinary tract infection and the like.

Claims (491)

1 . A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (I):

wherein:

A is

wherein the *-T-U—V— element is selected from the following:

a. *—C(R 21 )═C(R 21 )—N(R 22 )—;

b. *—C(R 21 )═C(R 21 )—O—;

c. *—N(R 22 )—C(R 21 )═C(R 21 )—;

d. *—N═C(R 21 )—N(R 23 )—;

e. *—N═C(R 21 )—O—;

f. *—N(R 22 )—N═C(R 21 )—;

g. *—C(R 21 )═N—N(R 22 )—;

h. *—C(R 21 )═N—O—; and

i. *—O—C(R 21 )═C(R 21 )—;

each R 21 is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; or two R 21 groups together with the carbon atoms to which they are attached join to form a ring;

each R 22 is independently H or optionally substituted alkyl; or a R 21 group and a R 22 group on adjacent atoms join to form a ring;

R 23 is optionally substituted alkyl;

n is 0-4;

m is 0-4;

R 1 , R 2 , R 3 and R 4 are each independently H, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, —COR 11 , —CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-CN, optionally substituted (C 1 -C 4 alkylene)-OR 11 , optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CO 2 R 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—SO 2 N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-O—SO 2 N(R 11 ) 2 , or optionally substituted (C 1 -C 4 alkylene)N(R 11 )—PO (optionally substituted C 4 -C 4 alkyl) 2 ;

or R 1 and R 2 are taken together to form an optionally substituted alkenyl, ═NR 11 , oxo, or thioxo;

or R 3 and R 4 are taken together to form an optionally substituted alkenyl; ═NR 11 , oxo, or thioxo;

X and Y are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl;

Z is H, -L-G, optionally substituted (C 1 -C 4 alkylene)-OCON(R 13 ) 2 , optionally substituted (C 1 -C 4 alkylene)-N(R 14 )CON(R 13 ) 2 , or optionally substituted (C 1 -C 4 alkylene)-SO 2 N(R 13 ) 2 , —SO 2 (R 13 );

L is a bond, optionally substituted C 1 -C 4 alkylene, —C(O)—, or —SO 2 —;

G is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, fluoroalkyl, oxo, thioxo, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —N(R 13 ) 2 , —OR 13 , or —CN;

each R 11 is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; or two R 11 groups together with the nitrogen to which they are attached join to form an optionally substituted N-heterocyclyl;

each R 12 is independently H or optionally substituted alkyl;

each R 13 is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; or two R 13 groups together with the nitrogen to which they are attached join to form an optionally substituted N-heterocyclyl; and

each R 14 is independently H or optionally substituted alkyl;

provided that when A is

and *-T-U—V is *—O—C(R 21 )═C(R 21 )—, R 3 is not H.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═C(R 21 )—N(R 22 )—.

3 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═C(R 21 )—O—.

4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N(R 22 )—C(R 21 )═C(R 21 )—.

5 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N═C(R 21 )—N(R 23 )—.

6 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N═C(R 21 )—O—.

7 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N(R 22 )—N═C(R 21 )—.

8 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═N—N(R 22 )—.

9 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═N—O—.

10 . The compound of any one of claims 1 - 9 , or a pharmaceutically acceptable salt thereof, wherein A is:

11 . The compound of any one of claims 1 - 9 , or a pharmaceutically acceptable salt thereof, wherein A is:

12 . The compound of any one of claims 1 - 9 , or a pharmaceutically acceptable salt thereof, wherein A is:

13 . A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (II):

wherein:

A is

wherein the *-T-U—V— element is selected from the following:

a. *—C(R 21 )═C(R 21 )—C(R 21 )═;

b. *—N═C(R 21 )—C(R 21 )═;

c. *—C(R 21 )═N—C(R 21 )═;

d. *—C(R 21 )═C(R 21 )—N═;

e. *—N═C(R 21 )—N═;

f. *—C(R 21 )═N—N═;

g. *—N═N—C(R 21 )═; and

h. *—N═N—N═;

n is 0-4;

m is 0-4;

or R 1 and R 2 are taken together to form an optionally substituted alkenyl, ═NR 11 , oxo, or thioxo;

or R 3 and R 4 are taken together to form an optionally substituted alkenyl; ═NR 11 , oxo, or thioxo;

L is a bond, optionally substituted C 1 -C 4 alkylene, —C(O)—, or —SO 2 —;

each R 12 is independently H or optionally substituted alkyl;

each R 14 is independently H or optionally substituted alkyl.

14 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═C(R 21 )—C(R 21 )═.

15 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N═C(R 21 )—C(R 21 )═.

16 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═N—C(R 21 )═.

17 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═C(R 21 )—N═.

18 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N═C(R 21 )—N═.

19 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═N—N═.

20 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N═N—C(R 21 )═.

21 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N═N—N═.

22 . The compound of any one of claims 13 - 21 , or a pharmaceutically acceptable salt thereof, wherein A is:

23 . The compound of any one of claims 13 - 21 , or a pharmaceutically acceptable salt thereof, wherein A is:

24 . The compound of any one of claims 13 - 21 , or a pharmaceutically acceptable salt thereof, wherein A is:

25 . A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (III):

wherein:

A is

wherein the *-T-U—V— element is selected from the following:

a. *—C(R 21 )═C(R 21 )—N(R 22 )—;

b. *—C(R 21 )═C(R 21 )—O—;

c. *—N(R 22 )—C(R 21 )═C(R 21 )—;

heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —N(R 13 ) 2 , —OR 13 , or —CN;

each R 12 is independently H or optionally substituted alkyl;

each R 14 is independently H or optionally substituted alkyl.

26 . The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═C(R 21 )—N(R 22 )—.

27 . The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═C(R 21 )—O—.

28 . The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N(R 22 )—C(R 21 )═C(R 21 )—.

29 . The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N═C(R 21 )—N(R 22 )—.

30 . The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N═C(R 21 )—O—.

31 . The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—N(R 22 )—N═C(R 21 )—.

32 . The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═N—N(R 22 )—.

33 . The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein the *-T-U—V— element is *—C(R 21 )═N—O—.

34 . The compound of any one of claims 25 - 33 , or a pharmaceutically acceptable salt thereof, wherein A is:

d. *—N═C(R 21 )—N(R 22 )—;

e. *—N═C(R 21 )—O—;

f. *—N(R 22 )—N═C(R 21 )—;

g. *—C(R 21 )═N—N(R 22 )—; and

h. *—C(R 21 )═N—O—;

each R 22 is independently H or optionally substituted alkyl; or a R 21 group and a R 22 group on adjacent atoms join to form a ring;

n is 0-4;

m is 0-4;

or R 1 and R 2 are taken together to form an optionally substituted alkenyl, ═NR 11 , oxo, or thioxo;

or R 3 and R 4 are taken together to form an optionally substituted alkenyl; ═NR 11 , oxo, or thioxo;

L is a bond, optionally substituted C 1 -C 4 alkylene, —C(O)—, or —SO 2 —;

35 . The compound of any one of claims 25 - 33 , or a pharmaceutically acceptable salt thereof, wherein A is:

36 . The compound of any one of claims 25 - 33 , or a pharmaceutically acceptable salt thereof, wherein A is:

37 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is H.

38 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is independently H or optionally substituted alkyl.

39 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is independently H or optionally substituted alkenyl.

40 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is independently H or optionally substituted carbocyclyl.

41 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is independently H or optionally substituted carbocyclylalkyl.

42 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is independently H or optionally substituted aryl.

43 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is independently H or optionally substituted aralkyl.

44 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is independently H or optionally substituted heterocyclyl.

45 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is independently H or optionally substituted heterocyclylalkyl.

46 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is independently H or optionally substituted heteroaryl.

47 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein each R 21 is independently H or optionally substituted heteroarylalkyl.

48 . The compound of any one of claims 1 - 36 , or a pharmaceutically acceptable salt thereof, wherein two R 21 groups together with the carbon atoms to which they are attached join to form a ring.

49 . The compound of any one of claims 1 - 48 , or a pharmaceutically acceptable salt thereof, wherein R 1 is unsubstituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, —COR 11 , —CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-CN, optionally substituted (C 1 -C 4 alkylene)-OR 11 , optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CO 2 R 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—SO 2 N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-O—SO 2 N(R 11 ) 2 , or optionally substituted (C 1 -C 4 alkylene)N(R 11 )—PO (optionally substituted C 1 -C 4 alkyl) 2 .

50 . The compound of any one of claims 1 - 48 , or a pharmaceutically acceptable salt thereof, wherein R 1 is unsubstituted alkyl, —COR 11 , —CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CO 2 R 11 , or optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CON(R 11 ) 2 .

51 . The compound of any one of claims 1 - 48 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —COR 11 , —CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 , or optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 .

52 . The compound of any one of claims 1 - 48 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —COR 11 .

53 . The compound of any one of claims 1 - 48 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —CON(R 11 ) 2 .

54 . The compound of any one of claims 1 - 48 , or a pharmaceutically acceptable salt thereof, wherein R 1 is optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 .

55 . The compound of any one of claims 1 - 48 , or a pharmaceutically acceptable salt thereof, wherein R 1 is optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 .

56 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein optionally substituted (C 1 -C 4 alkylene) is —CH 2 —.

57 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein each R 11 is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; or two R 11 groups together with the nitrogen to which they are attached join to form an optionally substituted N-heterocyclyl.

58 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is H.

59 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is optionally substituted alkyl.

60 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is hydroxy substituted alkyl.

61 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is fluoro substituted alkyl.

62 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is 2-fluoroethyl.

63 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is fluoromethyl.

64 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is difluoro substituted alkyl.

65 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is 2,2-difluoroethyl.

66 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is difluoromethyl.

67 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is trifluoro substituted alkyl.

68 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is 2,2,2-trifluoroethyl.

69 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is trifluoromethyl.

70 . The compound of any one of claims 1 - 32 , or a pharmaceutically acceptable salt thereof, wherein R 11 is amino substituted alkyl.

71 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is cyano substituted alkyl.

72 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is optionally substituted alkenyl.

73 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is optionally substituted carbocyclyl.

74 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is optionally substituted carbocyclylalkyl.

75 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is optionally substituted heterocyclyl.

76 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is optionally substituted heterocyclylalkyl.

77 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is optionally substituted heteroaryl.

78 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is optionally substituted heteroarylalkyl.

79 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein two R 11 groups together with the nitrogen to which they are attached join to form an optionally substituted N-heterocyclyl.

80 . The compound of any one of claims 1 - 55 , or a pharmaceutically acceptable salt thereof, wherein R 11 is vinyl, propan-2-yl, methyl, ethyl, cyclopropyl, cyclopentyl, azentidin-1-yl or allyl.

81 . The compound of any one of claims 1 - 80 , or a pharmaceutically acceptable salt thereof, wherein R 2 is H.

82 . The compound of any one of claims 1 - 81 , or a pharmaceutically acceptable salt thereof, wherein R 3 is H.

83 . The compound of any one of claims 1 - 82 , or a pharmaceutically acceptable salt thereof, wherein R 4 is H.

84 . The compound of any one of claims 1 - 83 , or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.

85 . The compound of any one of claims 1 - 83 , or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.

86 . The compound of any one of claims 1 - 85 , or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.

87 . The compound of any one of claims 1 - 85 , or a pharmaceutically acceptable salt thereof, wherein m is 1 or 2.

88 . The compound of any one of claims 1 - 87 , or a pharmaceutically acceptable salt thereof, wherein X is halogen.

89 . The compound of any one of claims 1 - 88 , or a pharmaceutically acceptable salt thereof, wherein Y is halogen.

90 . The compound of any one of claims 1 - 89 , or a pharmaceutically acceptable salt thereof, wherein Z is -L-G, optionally substituted (C 1 -C 4 alkylene)-OCON(R 13 ) 2 , optionally substituted (C 1 -C 4 alkylene)-N(R 14 )CON(R 13 ) 2 , or optionally substituted (C 1 -C 4 alkylene)-SO 2 N(R 13 ) 2 .

91 . The compound of any one of claims 1 - 90 , or a pharmaceutically acceptable salt thereof, wherein Z is -L-G.

92 . The compound of any one of claims 1 - 89 , or a pharmaceutically acceptable salt thereof, wherein Z is morpholinomethyl, (8-oxa-3-azabicyclo[3.2.1]octan-3-yl) methyl, (2-oxa-5-azabicyclo[2.2.1]heptan-5-yl) methyl, (1,1-dioxidothiomorpholino) methyl, (oxetan-3-ylamino) methyl, ((methoxycyclobutyl)amino)methyl, (methylpiperazin-1-yl)methyl, (cyanopyrrolidin-1-yl) methyl, or (methoxypyrrolidin-1-yl) methyl.

93 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein L is a bond or optionally substituted C 1 -C 4 alkylene.

94 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein L is a bond.

95 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein L is an optionally substituted C 1 -C 4 alkylene.

96 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein L is optionally substituted C 1 .

97 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein L is —CH 2 —.

98 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein G is optionally substituted alkyl.

99 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein G is optionally substituted heterocyclyl.

100 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein G is optionally substituted morpholinyl, piperidinyl, piperazinyl, pyrolidinyl, imidazolyl, imidazolidinyl.

101 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein G is optionally substituted morpholinyl.

102 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein G is unsubstituted morpholinyl

103 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein G is optionally substituted heteroaryl.

104 . The compound of any one of claims 1 - 91 or a pharmaceutically acceptable salt thereof, wherein G is —N(R 13 ) 2 .

105 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein G is —OR 13 .

106 . The compound of any one of claims 1 - 91 , or a pharmaceutically acceptable salt thereof, wherein G is —CN.

107 . The compound of any one of claims 1 - 106 , or a pharmaceutically acceptable salt thereof, wherein each R 13 is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; or two R 13 groups together with the nitrogen to which they are attached join to form an optionally substituted N-heterocyclyl.

108 . The compound of any one of claims 1 - 106 , or a pharmaceutically acceptable salt thereof, wherein R 13 is H.

109 . The compound of any one of claims 1 - 106 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted alkyl.

110 . The compound of any one of claims 1 - 106 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted carbocyclyl.

111 . The compound of any one of claims 1 - 106 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted carbocyclylalkyl.

112 . The compound of any one of claims 1 - 106 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted heterocyclyl.

113 . The compound of any one of claims 1 - 106 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted heterocyclylalkyl.

114 . The compound of any one of claims 1 - 106 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted heteroaryl.

115 . The compound of any one of claims 1 - 106 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted heteroarylalkyl.

116 . The compound of any one of claims 1 - 106 , or a pharmaceutically acceptable salt thereof, wherein two R 13 groups together with the nitrogen to which they are attached join to form an optionally substituted N-heterocyclyl.

117 . A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (IV):

wherein:

A is O or S;

L is *—CR 1 R 2 —CR 3 R 4 —; *—N(R 5 )—CR 3 R 4 —; *—CR 1 R 2 —N(R 5 )—; *—O—CR 3 R 4 —; *—CR 4 R 2 —O—; *—S—CR 3 R 4 —; *—CR 1 R 2 —S—; *—N(R 5 )—C(O)—; *—C(O)—N(R 5 )—; *—N(R 5 )—S(O) 2 —; *—S(O) 2 —N(R 5 )—, or

wherein the * denotes a bond to the hydroxypyrimidin-4(3H)-one ring or hydroxypyrimidin-4(3H)-thione ring;

R 1 or R 3 are each independently H, optionally alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, —COR 11 , —CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-OR 11 , optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CO 2 R 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-SO 2 N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-SO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—SO 2 R 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—SO 2 N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-O—SO 2 N(R 11 ) 2 , or optionally substituted (C 1 -C 4 alkylene)N(R 11 )—PO (optionally substituted C 1 -C 4 alkyl) 2 ;

R 2 is H or optionally substituted C 1 -C 3 alkyl; or R 1 and R 2 are taken together to form an optionally substituted alkenyl;

R 4 is H or optionally substituted C 1 -C 3 alkyl; or R 3 and R 4 are taken together to form an optionally substituted alkenyl;

each R 5 is independently H or optionally substituted alkyl;

each X 1 , X 2 , X 3 , or X 4 is N, N + —O − , or C—R 6 ;

X 5 is N, N + —O − , or C—Z;

each R 6 is independently H, halogen, —OH, or optionally substituted C 1 -C 3 alkyl;

each Y 1 , Y 2 , Y 3 , or Y 4 is N, N + —O − , or C—R 7 ;

R 7 is halogen, —OH, or optionally substituted C 1 -C 3 alkyl;

Z is H, -L1-G, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl;

L1 is a bond, optionally substituted C 1 -C 4 alkylene, —C(O)—, or —SO 2 —;

G is optionally substituted heterocyclyl, optionally substituted heteroaryl, —N(R 13 ) 2 , —OR 13 , —CN, —OCON(R 13 ) 2 , or —N(R 14 )CON(R 13 ) 2 ;

each R 12 is independently H or optionally substituted alkyl;

each R 14 is independently H or optionally substituted alkyl;

with the provision if L is *—CR 1 R 2 —CR 3 R 4 —, then at least one of X 1 , X 2 , X 3 , X 4 , X 5 , Y 1 , Y 2 , Y 3 , or Y 4 is not C.

118 . A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (V):

wherein:

A is O or S;

wherein the * denotes a bond to the hydroxypyrimidin-4(3H)-one ring or hydroxypyrimidin-4(3H)-thione ring;

R 2 is H or optionally substituted C 1 -C 3 alkyl; or R 1 and R 2 are taken together to form an optionally substituted alkenyl;

R 4 is H or optionally substituted C 1 -C 3 alkyl; or R 3 and R 4 are taken together to form an optionally substituted alkenyl;

each R 5 is independently H or optionally substituted alkyl;

each X 1 , X 2 , X 3 , or X 4 is N, N + —O − , or C—R 6 ;

X 5 is N, N + —O − , or C—R 7 ;

each R 6 is independently H, halogen, —OH, or optionally substituted C 1 -C 3 alkyl;

each Y 1 , Y 2 , Y 3 , or Y 4 is N, N + —O − , or C—R 7 ;

R 7 is halogen, —OH, or optionally substituted C 1 -C 3 alkyl;

Z is H, -L1-G, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl;

L1 is a bond, optionally substituted C 1 -C 4 alkylene, —C(O)—, or —SO 2 —;

G is optionally substituted heterocyclyl, optionally substituted heteroaryl, —N(R 13 ) 2 , —OR 13 , —CN, —OCON(R 13 ) 2 , or —N(R 14 )CON(R 13 ) 2 ;

each R 12 is independently H or optionally substituted alkyl;

each R 14 is independently H or optionally substituted alkyl;

W is a bond, —S—, —SO—, —SO 2 —, —O—, —CR 1 R 3 —, —C≡C—C≡C—, —C(═CR 1 H)—, *—CR 1 ═CR 3 —; *—CR 1 R 2 —CR 3 R 4 —; *—N(R 5 )—CR 3 R 4 —; *—CR 1 R 2 —N(R 5 )—; *—O—CR 3 R 4 —; *—CR 1 R 2 —O—; *—S—CR 3 R 4 —; *—CR 4 R 2 —S—; *—N(R 5 )—C(O)—; *—C(O)—N(R 5 )—; *—N(R 5 )—S(O) 2 —; or *—S(O) 2 —N(R 5 )—, wherein the * denotes a bond to the ring having the X groups.

119 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein A is O.

120 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein L is *—CR 1 R 2 —CR 3 R 4 —.

121 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein L is *—N(R 5 )—CR 3 R 4 —.

122 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein L is *—CR 1 R 2 —N(R 5 )—.

123 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein L is *—CR 1 R 2 —O—.

124 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein L is *—CR 1 R 2 —S—.

125 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein L is *—N(R 5 )—C(O)—.

126 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein L is *—C(O)—N(R 5 )—.

127 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein L is *—N(R 5 )—S(O) 2 —.

128 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 is —COR 11 .

129 . The compound of claim 117 or 118 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 is —CON(R 11 ) 2 .

130 . The compound of any one of claims 117 - 129 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 is optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 .

131 . The compound of any one of claims 117 - 129 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 is optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 .

132 . The compound of any one of claims 117 - 129 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 is optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CO 2 R 11 .

133 . The compound of any one of claims 117 - 132 , or a pharmaceutically acceptable salt thereof, wherein R 2 is H.

134 . The compound of any one of claims 117 - 133 , or a pharmaceutically acceptable salt thereof, wherein R 4 is H.

135 . The compound of any one of claims 117 - 134 , or a pharmaceutically acceptable salt thereof, wherein R 5 is H.

136 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 1 , X 2 and X 3 are CR 6 and X 4 is N.

137 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 1 , X 2 and X 4 are CR 6 and X 3 is N.

138 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 1 , X 3 and X 4 are CR 6 and X 2 is N.

139 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 2 , X 3 and X 4 are CR 6 and X 1 is N.

140 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 2 is CR 6 , X 3 and X 4 is N.

141 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 3 is CR 6 , X 2 and X 4 is N.

142 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 4 is CR 6 , X 3 and X 2 is N.

143 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 2 and X 3 is CR 6 , X 1 and X 4 is N.

144 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 2 and X 4 is CR 6 , X 1 and X 3 is N.

145 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 3 and X 4 is CR 6 , X 1 and X 2 is N.

146 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 5 is C—Z.

147 . The compound of any one of claims 117 - 135 , or a pharmaceutically acceptable salt thereof, wherein X 5 is N.

148 . The compound of any one of claims 117 - 147 , or a pharmaceutically acceptable salt thereof, wherein R 6 is halogen.

149 . The compound of any one of claims 117 - 147 , or a pharmaceutically acceptable salt thereof, wherein R 6 is H.

150 . The compound of any one of claims 117 - 147 , or a pharmaceutically acceptable salt thereof, wherein R 6 is —OH.

151 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein Y 1 , Y 2 and Y 3 are CR 7 and Y 4 is N.

152 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein Y 1 , Y 2 and Y 4 are CR 7 and Y 3 is N.

153 . The compound of any one of claims 117 - 150 or a pharmaceutically acceptable salt thereof, wherein Y 1 , Y 3 and Y 4 are CR 7 and Y 2 is N.

154 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein Y 2 , Y 3 and Y 4 are CR 7 and Y 1 is N.

155 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein Y 1 and Y 2 is CR 7 , Y 3 and Y 4 is N.

156 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein Y 1 and Y 3 is CR 7 , Y 2 and Y 4 is N.

157 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein Y 1 and Y 4 is CR 7 , Y 3 and Y 2 is N.

158 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein Y 2 and Y 3 is CR 7 , Y 1 and Y 4 is N.

159 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein Y 2 and Y 4 is CR 7 , Y 1 and Y 3 is N.

160 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein Y 3 and Y 4 is CR 7 , Y 1 and Y 2 is N.

161 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein R 7 is halogen.

162 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein R 7 is H.

163 . The compound of any one of claims 117 - 150 , or a pharmaceutically acceptable salt thereof, wherein R 7 is —OH.

164 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein Z is H.

165 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein Z is haloalkyl.

166 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein Z is hydroxyalkyl.

167 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein Z is -L1-G.

168 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein L1 is a bond.

169 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein L1 is a C 1 -C 4 alkylene.

170 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein L1 is C 1 alkylene.

171 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein L1 is —CH 2 —.

172 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein G is —N(R 13 ) 2 —.

173 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein R 13 is H.

174 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted alkyl.

175 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein R 13 is hydroxy substituted alkyl.

176 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted heterocycle.

177 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein R 13 is alkoxy substituted heterocycle.

178 . The compound of any one of claims 117 - 163 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted cycloalkyl.

179 . The compound of any one of claims 117 - 178 , or a pharmaceutically acceptable salt thereof, wherein W is a bond.

180 . The compound of any one of claims 117 - 178 , or a pharmaceutically acceptable salt thereof, wherein W is —C≡C—C≡C—.

181 . The compound of any one of claims 117 - 178 , or a pharmaceutically acceptable salt thereof, wherein W is *—CR 1 ═CR 3 —.

182 . The compound of any one of claims 117 - 178 , or a pharmaceutically acceptable salt thereof, wherein W is *—CR 1 R 2 —CR 3 R 4 —.

183 . The compound of any one of claims 117 - 178 , or a pharmaceutically acceptable salt thereof, wherein W is —S—.

184 . The compound of any one of claims 117 - 178 , or a pharmaceutically acceptable salt thereof, wherein W is —O—.

185 . The compound of any one of claims 117 - 178 , or a pharmaceutically acceptable salt thereof, wherein W is —CR 1 R 3 —.

186 . A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (VI):

wherein:

A is O or S;

L is *—CR 1 R 2 —CR 3 R 4 —; *—N(R 5 )—CR 3 R 4 —; *—O—CR 3 R 4 —; *—S—CR 3 R 4 —; *—N(R 5 )—C(O)—; *—C(O)—N(R 5 )—; *—N(R 5 )—S(O) 2 —; *—S(O) 2 —N(R 5 )—, or

wherein the * denotes a bond to the hydroxypyrimidin-4(3H)-one ring or hydroxypyrimidin-4(3H)-thione ring;

R 2 is H or optionally substituted C 1 -C 3 alkyl; or R 1 and R 2 are taken together to form an optionally substituted alkenyl;

R 4 is H or optionally substituted C 1 -C 3 alkyl; or R 3 and R 4 are taken together to form an optionally substituted alkenyl;

each R 5 is independently H or optionally substituted alkyl;

each X 1 , X 2 , X 3 , or X 4 is N, N + —O − , or C—R 6 ;

X 5 is N, N + —O − , or C—Z;

each R 6 is independently H, halogen, —OH, or optionally substituted C 1 -C 3 alkyl;

each Y 1 , Y 2 , Y 3 , or Y 4 is N or C—R 7 ;

R 7 is halogen, —OH, or optionally substituted C 1 -C 3 alkyl;

Z is H, -L1-G, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl;

L1 is a bond, optionally substituted C 1 -C 4 alkylene, —C(O)—, or —SO 2 —;

G is optionally substituted heterocyclyl, optionally substituted heteroaryl, —N(R 13 ) 2 , —OR 13 , —CN, —OCON(R 13 ) 2 , or —N(R 14 )CON(R 13 ) 2 ;

each R 12 is independently H or optionally substituted alkyl;

each R 14 is independently H or optionally substituted alkyl;

W is a bond, —S—, —SO—, —SO 2 —, —O—, —CR 4 R 3 —, —C≡C—C≡C—, —C(═CR 1 H)—, *—CR 1 ═CR 3 —; *—CR 1 R 2 —CR 3 R 4 —; *—N(R 5 )—CR 3 R 4 —; *—CR 1 R 2 —N(R 5 )—; *—O—CR 3 R 4 —; *—CR 4 R 2 —O—; *—S—CR 3 R 4 —; *—CR 4 R 2 —S—; *—N(R 5 )—C(O)—; *—C(O)—N(R 5 )—; *—N(R 5 )—S(O) 2 —; or *—S(O) 2 —N(R 5 )—, wherein the * denotes a bond to the ring having the X groups.

187 . The compound of claim 186 , or a pharmaceutically acceptable salt thereof, wherein A is O.

188 . The compound of claim 186 or 187 , or a pharmaceutically acceptable salt thereof, wherein L is *—CR 1 R 2 —CR 3 R 4 —.

189 . The compound of claim 186 or 187 , or a pharmaceutically acceptable salt thereof, wherein L is *—N(R 5 )—CR 3 R 4 —.

190 . The compound of claim 186 or 187 , or a pharmaceutically acceptable salt thereof, wherein L is *—CR 1 R 2 —N(R 5 )—.

191 . The compound of claim 186 or 187 , or a pharmaceutically acceptable salt thereof, wherein L is *—CR 1 R 2 —O—.

192 . The compound of claim 186 or 187 , or a pharmaceutically acceptable salt thereof, wherein L is *—CR 1 R 2 —S—.

193 . The compound of claim 186 or 187 , or a pharmaceutically acceptable salt thereof, wherein L is *—N(R 5 )—C(O)—.

194 . The compound of claim 186 or 187 , or a pharmaceutically acceptable salt thereof, wherein L is *—C(O)—N(R 5 )—.

195 . The compound of claim 186 or 187 , or a pharmaceutically acceptable salt thereof, wherein L is *—N(R 5 )—S(O) 2 —.

196 . The compound of any one of claims 186 - 195 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 is —COR 11 .

197 . The compound of any one of claims 186 - 195 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 is —CON(R 11 ) 2 .

198 . The compound of any one of claims 186 - 195 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 is optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 .

199 . The compound of any one of claims 186 - 195 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 is optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 .

200 . The compound of any one of claims 186 - 195 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 is optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CO 2 R 11 .

201 . The compound of any one of claims 186 - 200 , or a pharmaceutically acceptable salt thereof, wherein R 2 is H.

202 . The compound of any one of claims 186 - 201 , or a pharmaceutically acceptable salt thereof, wherein R 4 is H.

203 . The compound of any one of claims 186 - 202 , or a pharmaceutically acceptable salt thereof, wherein R 5 is H.

204 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 1 , X 2 and X 3 are CR 6 and X 4 is N.

205 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 1 , X 2 and X 4 are CR 6 and X 3 is N.

206 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 1 , X 3 and X 4 are CR 6 and X 2 is N.

207 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 2 , X 3 and X 4 are CR 6 and X 1 is N.

208 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 2 is CR 6 , X 3 and X 4 is N.

209 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 3 is CR 6 , X 2 and X 4 is N.

210 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 4 is CR 6 , X 3 and X 2 is N.

211 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 2 and X 3 is CR 6 , X 1 and X 4 is N.

212 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 2 and X 4 is CR 6 , X 1 and X 3 is N.

213 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 3 and X 4 is CR 6 , X 1 and X 2 is N.

214 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 5 is C—Z.

215 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein X 5 is N.

216 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein R 6 is halogen.

217 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein R 6 is H.

218 . The compound of any one of claims 186 - 203 , or a pharmaceutically acceptable salt thereof, wherein R 6 is —OH.

219 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein Y 1 and Y 2 is CR 7 , Y 4 is N.

220 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein Y 1 and Y 4 is CR 7 , Y 2 is N.

221 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein Y 2 and Y 4 is CR 7 , Y 1 is N.

222 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein Y 1 is CR 7 , Y 2 and Y 4 is N.

223 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is CR 7 , Y 1 and Y 4 is N.

224 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein Y 4 is CR 7 , Y 1 and Y 2 is N.

225 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein W is a bond.

226 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein W is —C≡C—C≡C—.

227 . The compound of any one of claims 186 - 218 or a pharmaceutically acceptable salt thereof, wherein W is *—CR 1 ═CR 3 —.

228 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein W is *—CR 1 R 2 —CR 3 R 4 —.

229 . The compound of any one of claims 186 - 218 or a pharmaceutically acceptable salt thereof, wherein W is —S—.

230 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein W is —O—.

231 . The compound of any one of claims 186 - 218 , or a pharmaceutically acceptable salt thereof, wherein W is —CR 1 R 3 —.

232 . The compound of any one of claims 186 - 231 , or a pharmaceutically acceptable salt thereof, wherein R 7 is halogen.

233 . The compound of any one of claims 186 - 231 , or a pharmaceutically acceptable salt thereof, wherein R 7 is H.

234 . The compound of any one of claims 186 - 231 , or a pharmaceutically acceptable salt thereof, wherein R 7 is —OH.

235 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein Z is H.

236 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein Z is haloalkyl.

237 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein Z is hydroxyalkyl.

238 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein Z is -L1-G.

239 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein L1 is a bond.

240 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein L1 is a C 1 -C 4 alkylene.

241 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein L1 is C 1 alkylene.

242 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein L1 is —CH 2 —.

243 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein G is —N(R 13 ) 2 —.

244 . The compound of any one of claims 186 - 234 or a pharmaceutically acceptable salt thereof, wherein R 13 is H.

245 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted alkyl.

246 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein R 13 is hydroxy substituted alkyl.

247 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted heterocycle.

248 . The compound of any one of claims 186 - 234 , or a pharmaceutically acceptable salt thereof, wherein R 13 is alkoxy substituted heterocycle.

249 . The compound of any one of claims 186 - 234 or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally substituted cycloalkyl.

250 . A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (VII):

wherein:

n is 0, 1, or 2;

m is 0, 1, or 2;

A 1 is OH or SH;

A 2 is O or S;

L is a bond, —CR 1 R 2 —, —N(R 5 )—, —O—, —S—, —SO 2 —, *—CR 1 R 2 —CR 3 R 4 —; *—N(R 5 )—CR 3 R 4 —; *—CR 1 R 2 —N(R 5 )—; *—O—CR 3 R 4 —; *—CR 1 R 2 —O—; *—S—CR 3 R 4 —; *—CR 4 R 2 —S—; *—N(R 5 )—C(O)—; *—C(O)—N(R 5 )—; *—N(R 5 )—S(O) 2 —; *—S(O) 2 —N(R 5 )—, or

wherein the * denotes a bond to the pyrimidin-4(3H)-one ring or pyrimidin-4(3H)-thione ring;

R 1 , R 2 , R 3 , R 4 , and R 5 are each independently H, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, —COR 11 , —CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-CN, optionally substituted (C 0 -C 4 alkylene)-OR 11 , optionally substituted (C 0 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—COR 11 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—CO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—SO 2 N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-O—SO 2 N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-N(R 12 )—SO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)-SO 2 R 11 , or optionally substituted (C 0 -C 4 alkylene)N(R 11 )—PO (optionally substituted C 0 -C 4 alkyl) 2 ;

or R 1 and R 2 are taken together to form an optionally substituted alkenyl, ═NR 11 , oxo, or thioxo;

or R 3 and R 4 are taken together to form an optionally substituted alkenyl; ═NR 11 , oxo, or thioxo;

R 6 is H, halogen, optionally substituted alkyl, hydroxyl, alkoxyl, cyano, amino, or nitro;

is phenyl,

W is a bond, —C≡C—, —C≡C—C≡C—, —S—, —SO—, —SO 2 —, —O—, —CR 1 R 3 —, —C(═CR 1 H)—, *—CR 1 ═CR 3 —; *—CR 1 R 2 —CR 3 R 4 —; *—N(R 5 )—CR 3 R 4 —; *—CR 1 R 2 —N(R 5 )—; *—O—CR 3 R 4 —; *—CR 1 R 2 —O—; *—S—CR 3 R 4 —; *—CR 4 R 2 —S—; *—N(R 5 )—C(O)—; *—C(O)—N(R 5 )—; *—N(R 5 )—S(O) 2 —; or *—S(O) 2 —N(R 5 )—, wherein the * denotes a bond to the ring having the Y groups;

is absent, phenyl, alkyl, cycloalkyl,

provided that if

is phenyl or pyridine, then

is not phenyl or pyridine; and

is phenyl or pyridine, then

is not phenyl or pyridine;

Z is H, -L2-G, optionally substituted (C 1 -C 4 alkylene)-OCON(R 13 ) 2 , optionally substituted (C 1 -C 4 alkylene)-N(R 14 )CON(R 13 ) 2 , or optionally substituted (C 1 -C 4 alkylene)-SO 2 N(R 13 ) 2 , —SO 2 (R 13 );

L2 is a bond, optionally substituted C 1 -C 4 alkylene, —C(O)—, or —SO 2 —;

each R 12 is independently H or optionally substituted alkyl;

each R 14 is independently H or optionally substituted alkyl.

251 . A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (VIIa):

wherein:

n is 0, 1, or 2;

m is 0, 1, or 2;

A 2 is O or S;

L is —CR 1 R 2 —, —N(R 5 )—, —O—, —S—, —SO 2 —, *—CR 1 R 2 —CR 3 R 4 —; *—N(R 5 )—CR 3 R 4 —; *—CR 1 R 2 —N(R 5 )—; *—O—CR 3 R 4 —;

*—CR 1 R 2 —O—; *—S—CR 3 R 4 —; *—CR 1 R 2 —S—; *—N(R 5 )—C(O)—; *—C(O)—N(R 5 )—; *—N(R 5 )—S(O) 2 —; *—S(O) 2 —N(R 5 )—: or

wherein the * denotes a bond to the hydroxypyrimidin-4(3H)-one ring or hydroxypyrimidin-4(3H)-thione ring;

R 1 or R 3 are each independently H, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, —COR 11 , —CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-CN, optionally substituted (C 0 -C 4 alkylene)-OR 11 , optionally substituted (C 0 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—COR 11 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—CO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-SO 2 N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-SO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—SO 2 N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—SO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)-O—SO 2 N(R 11 ) 2 , or optionally substituted (C 0 -C 4 alkylene)N(R 11 )—PO (optionally substituted C 1 -C 4 alkyl) 2 ;

R 2 , R 4 , and R 5 are each independently H or optionally substituted C 1 -C 3 alkyl;

is phenyl,

W is a bond, —C≡C—, —C≡C—C≡C—, —S—, —SO—, —SO 2 —, —O—, —CR 1 R 3 —, —C(═CR 1 H)—, *—CR 1 ═CR 3 —; *—CR 1 R 2 —CR 3 R 4 —; *—N(R 5 )—CR 3 R 4 —; *—CR 1 R 2 —N(R 5 )—; *—O—CR 3 R 4 —; *—CR 4 R 2 —O—; *—S—CR 3 R 4 —; *—CR 4 R 2 —S—; *—N(R 5 )—C(O)—; *—C(O)—N(R 5 )—; *—N(R 5 )—S(O) 2 —; or *—S(O) 2 —N(R 5 )—, wherein the * denotes a bond to the ring having the Y groups;

is absent, phenyl, alkyl, cycloalkyl,

provided that if

is phenyl or pyridine, then

is not phenyl or pyridine; and

is phenyl or pyridine, then

is not phenyl or pyridine;

X is halogen or optionally substituted C 1 -C 3 alkyl;

Y is halogen or optionally substituted C 1 -C 3 alkyl;

Z is H, optionally substituted alkyl, -L2-G, optionally substituted (C 1 -C 4 alkylene)-OCON(R 13 ) 2 , optionally substituted (C 1 -C 4 alkylene)-N(R 14 )CON(R 13 ) 2 , or optionally substituted (C 1 -C 4 alkylene)-SO 2 N(R 13 ) 2 ;

L2 is a bond, optionally substituted C 1 -C 4 alkylene, —C(O)—, or —SO 2 —;

G is optionally substituted heterocyclyl, optionally substituted heteroaryl, —N(R 13 ) 2 , —OR 13 , halogen, or —CN;

each R 12 is independently H or optionally substituted alkyl;

each R 14 is independently H or optionally substituted alkyl.

252 . The compound of either of claims 250 or 251 , or a pharmaceutically acceptable salt thereof, wherein R 1 or R 3 are each independently H, unsubstituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, —COR 11 , —CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-CN, optionally substituted (C 0 -C 4 alkylene)-OR 11 , optionally substituted (C 0 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—COR 11 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—CO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-SO 2 N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-SO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—SO 2 N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)N(R 12 )—SO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)-O—SO 2 N(R 11 ) 2 , or optionally substituted (C 0 -C 4 alkylene)N(R 11 )—PO (optionally substituted C 1 -C 4 alkyl) 2 .

253 . The compound of any one of claims 250 - 252 , or a pharmaceutically acceptable salt thereof, wherein R 1 is unsubstituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, —COR 11 , —CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-CN, optionally substituted (C 1 -C 4 alkylene)-OR 11 , optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CO 2 R 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—SO 2 N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-O—SO 2 N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-SO 2 N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-SO 2 R 11 , or optionally substituted (C 1 -C 4 alkylene)N(R 11 )—PO (optionally substituted C 1 -C 4 alkyl) 2 .

254 . The compound of any one of claims 250 - 253 , or a pharmaceutically acceptable salt thereof, wherein R 1 is optionally substituted heterocyclyl, —CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-CN, optionally substituted (C 1 -C 4 alkylene)-OR 11 , optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 , optionally substituted (C 1 -C 4 alkylene)-SO 2 N(R 11 ) 2 , or optionally substituted (C 1 -C 4 alkylene)-SO 2 R 11 .

255 . The compound of any one of claims 250 - 254 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —CON(R 11 ) 2 , (C 1 -C 4 alkylene)-N(R 11 ) 2 , or (C 1 -C 4 alkylene)N(R 12 )—COR 11 .

256 . The compound of any one of claims 250 - 255 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —CON(R 11 ) 2 , (C 1 alkylene)-N(R 11 ) 2 , or (C 1 alkylene)N(R 12 )—COR 11 .

257 . The compound of any one of claims 250 - 256 , or a pharmaceutically acceptable salt thereof, wherein R 3 is unsubstituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, —COR 11 , —CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-CN, optionally substituted (C 1 -C 4 alkylene)-OR 11 , optionally substituted (C 1 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—COR 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CO 2 R 11 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—CON(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)N(R 12 )—SO 2 N(R 11 ) 2 , optionally substituted (C 1 -C 4 alkylene)-O—SO 2 N(R 11 ) 2 , or optionally substituted (C 1 -C 4 alkylene)N(R 11 )—PO (optionally substituted C 1 -C 4 alkyl) 2 .

258 . The compound of any one of claims 250 - 257 , or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are H.

259 . The compound of any one of claims 250 - 258 , or a pharmaceutically acceptable salt thereof, wherein R 2 is H.

260 . The compound of any one of claims 250 - 259 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are H.

261 . The compound of any one of claims 250 - 260 , or a pharmaceutically acceptable salt thereof, wherein n is 0.

262 . The compound of any one of claims 250 - 260 , or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.

263 . The compound of any one of claims 250 - 261 , or a pharmaceutically acceptable salt thereof, wherein m is 0.

264 . The compound of any one of claims 250 - 261 , or a pharmaceutically acceptable salt thereof, wherein m is 1 or 2.

265 . The compound of any one of claims 250 - 264 , or a pharmaceutically acceptable salt thereof, wherein X is halogen.

266 . The compound of any one of claims 250 - 265 , or a pharmaceutically acceptable salt thereof, wherein Y is halogen.

267 . The compound of any one of claims 250 - 266 , or a pharmaceutically acceptable salt thereof, wherein Z is H, alkyl, -L2-G, optionally substituted (C 1 -C 4 alkylene)-OCON(R 13 ) 2 , optionally substituted (C 1 -C 4 alkylene)-N(R 14 )CON(R 13 ) 2 , or optionally substituted (C 1 -C 4 alkylene)-SO 2 N(R 13 ) 2 .

268 . The compound of any one of claims 250 - 267 , or a pharmaceutically acceptable salt thereof, wherein Z is H, alkyl, -L2-G; wherein L2 is a bond, optionally substituted C 1 -C 4 alkylene, —C(O)—; and G is optionally substituted heterocyclyl, —N(R 13 ) 2 , —OR 13 , halogen, or —CN.

269 . The compound of any one of claims 250 - 268 , or a pharmaceutically acceptable salt thereof, wherein Z is H, alkyl, or -L2-G, wherein L2 is C 1 -C 4 alkylene and G is heterocyclyl.

270 . The compound of any one of claims 250 - 269 , or a pharmaceutically acceptable salt thereof, wherein Z is H, alkyl, or -L2-G, wherein L2 is C 1 -C 4 alkylene and G is morpholino.

271 . The compound of any one of claims 250 - 270 , or a pharmaceutically acceptable salt thereof, wherein each R 11 is independently H, haloalkyl, alkyl, alkenyl, carbocyclyl, carbocyclylalkyl; or two R 11 groups together with the nitrogen to which they are attached join to form an optionally substituted N-heterocyclyl.

272 . The compound of any one of claims 250 - 270 , or a pharmaceutically acceptable salt thereof, wherein each R 11 is independently H, haloalkyl, alkyl, or alkenyl.

273 . The compound of any one of claims 250 - 270 , or a pharmaceutically acceptable salt thereof, wherein each R 11 is independently H, fluoroalkyl, alkyl, or alkenyl.

274 . The compound of any one of claims 250 - 270 , or a pharmaceutically acceptable salt thereof, wherein each R 11 is independently H, C 1-6 fluoroalkyl, C 1-6 alkyl, or C 3 alkenyl.

275 . The compound of any one of claims 250 - 270 , or a pharmaceutically acceptable salt thereof, wherein each R 11 is independently H, C 1-3 fluoroalkyl, C 1-6 methyl, or C 3 alkenyl.

276 . The compound of any one of claims 250 - 275 , or a pharmaceutically acceptable salt thereof, wherein each R 13 is independently H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl; or two R 13 groups together with the nitrogen to which they are attached join to form an optionally substituted N-heterocyclyl; and each R 14 is independently H or optionally substituted alkyl.

277 . The compound of any one of claims 250 - 275 , or a pharmaceutically acceptable salt thereof, wherein each R 13 is independently H, alkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, heterocyclylalkyl; or two R 13 groups together with the nitrogen to which they are attached join to form an N-heterocyclyl; and each R 14 is H.

278 . The compound of any one of claims 250 - 275 , or a pharmaceutically acceptable salt thereof, wherein each R 13 is independently H, or alkyl; or two R 13 groups together with the nitrogen to which they are attached join to form an N-heterocyclyl; and each R 14 is H.

279 . The compound of any one of claims 250 - 278 , or a pharmaceutically acceptable salt thereof, wherein

is phenyl,

280 . The compound of any one of claims 250 - 279 , or a pharmaceutically acceptable salt thereof, wherein

is absent, phenyl, alkyl, cycloalkyl,

281 . The compound of any one of claims 250 - 279 , or a pharmaceutically acceptable salt thereof, wherein

is phenyl, alkyl, cycloalkyl,

282 . The compound of any one of claims 250 - 279 , or a pharmaceutically acceptable salt thereof, wherein

is phenyl or cyclopropyl.

283 . The compound of any one of claims 250 - 282 , or a pharmaceutically acceptable salt thereof, wherein W is a bond, —C≡C—, —C≡C—C≡C—, or —CH═CH—.

284 . The compound of any one of claims 250 - 283 , or a pharmaceutically acceptable salt thereof, wherein W is a bond, —C≡C—, or —C≡C—C≡C—.

285 . A pharmaceutical composition comprising a compound of any one of claims 1 - 284 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

286 . A method of inhibiting UDP-{3-O—[(R)-3-hydroxymyristoyl]}-N-acetylglucosamine deacetylase enzyme comprising contacting the enzyme with a compound of any one of claims 1 - 284 .

287 . A method for treating bacterial infection in a patient in need thereof comprising administering to the patient a composition of claim 285 .

Assignments (5)

MERGER AND CHANGE OF NAME Recorded Jan 13, 2023

From: FORGE THERAPEUTICS, INC.; BLACKSMITH MEDICINES, INC.

To: BLACKSMITH MEDICINES, INC.

Reel/Frame 062376/0817 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2021

From: TENG, MIN; NAMMALWAR, BASKAR; LI, XIAOMING; PUERTA, DAVID T.

To: FORGE THERAPEUTICS, INC.

Reel/Frame 057417/0222 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2021

From: YULE, IAN; PARKES, ALASTAIR; TYE, HEATHER; ATTON, HOLLY; WILLIAMS, HELEN; FAULKNER, ADELE; CONVERS-REIGNIER, SERGE